Manager × security

Candriam S.C.A. REGN holdings history

Who else holds this security? →

REGENERON PHARMACEUTICALS · CUSIP 75886F107 · CIK 1537014

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Candriam S.C.A. reported 195.67K REGN (shares), valued at $121.89M, or 0.55% of its reported non-derivative portfolio. Filed 2026-08-13.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
0.55%
Shares
195.67K
195,674
Reported value
$121.89M
USD

Shares increased 4.98%; reported value decreased 15.36%, and weight changed -0.20 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.55%195,674SEC filing ↗Filed Aug 13, 2026Combination report
Q1 20260.75%186,388SEC filing ↗Filed Apr 30, 2026Combination report
Q4 20250.79%205,332SEC filing ↗Filed Apr 30, 2026AmendedCombination report
Q3 20250.50%169,495SEC filing ↗Filed Nov 6, 2025
Q2 20250.43%142,208SEC filing ↗Filed Aug 8, 2025
Q1 20250.85%214,941SEC filing ↗Filed May 14, 2025
Q4 20241.07%261,498SEC filing ↗Filed Feb 7, 2025
Q3 20241.53%252,525SEC filing ↗Filed Nov 13, 2024
Q2 20241.28%200,708SEC filing ↗Filed Aug 5, 2024
Q1 20241.34%217,771SEC filing ↗Filed May 6, 2024
Q4 20231.46%241,618SEC filing ↗Filed Feb 14, 2024
Q3 20231.79%290,310SEC filing ↗Filed Nov 13, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20231.79%290,310$238.91MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 13, 2023
Q4 20231.46%241,618$212.22MShares decreased 16.77%; reported value decreased 11.17%, and weight changed -0.33 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 20241.34%217,771$209.60MShares decreased 9.87%; reported value decreased 1.23%, and weight changed -0.12 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 6, 2024
Q2 20241.28%200,708$210.94MShares decreased 7.84%; reported value increased 0.64%, and weight changed -0.06 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 5, 2024
Q3 20241.53%252,525$265.45MShares increased 25.82%; reported value increased 25.84%, and weight changed +0.25 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2024
Q4 20241.07%261,498$186.27MShares increased 3.55%; reported value decreased 29.83%, and weight changed -0.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 7, 2025
Q1 20250.85%214,941$136.32MShares decreased 17.80%; reported value decreased 26.82%, and weight changed -0.22 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 14, 2025
Q2 20250.43%142,208$74.66MShares decreased 33.84%; reported value decreased 45.23%, and weight changed -0.42 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 8, 2025
Q3 20250.50%169,495$95.30MShares increased 19.19%; reported value increased 27.64%, and weight changed +0.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 6, 2025
Q4 20250.79%205,332$158.50MShares increased 21.14%; reported value increased 66.31%, and weight changed +0.29 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Apr 30, 2026
Q1 20260.75%186,388$144.01MShares decreased 9.23%; reported value decreased 9.14%, and weight changed -0.04 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Apr 30, 2026
Q2 20260.55%195,674$121.89MShares increased 4.98%; reported value decreased 15.36%, and weight changed -0.20 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2026
Candriam S.C.A. · REGENERON PHARMACEUTICALS

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1537014","quarter":"2026Q2","cusip":"75886F107"}

get_institutional_manager_history
{"cik":"1537014","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.